Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 2:31 PM
Ignite Modification Date: 2025-12-25 @ 1:04 PM
NCT ID: NCT02389959
Description: None
Frequency Threshold: 0
Time Frame: 6 months.
Study: NCT02389959
Study Brief: Intranasal Bevacizumab for HHT-Related Epistaxis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Bevacizumab Bevacizumab mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL), injected into each side of the nose. 0 None 0 20 0 20 View
Saline Control Placebo (4mL of saline) mixed by the Stanford Hospital Pharmacy as a control. 0 None 0 20 0 20 View
Serious Events(If Any):
Other Events(If Any):